Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bolis

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
International Journal of Cancer|October 23, 1997
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cellsV Ramakrishna, D R Negri, V Brusic, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancerF Crippa, G Bolis, E Seregni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxelM A Bookman, H Malmström, G Bolis, et al.
Gynecologic Oncology|January 16, 1999
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancerG Bolis, F Parazzini, G Scarfone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2006
Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II studyG Bolis, S Danese, S Tateo, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 1998
Approaches to implement bispecific antibody treatment of ovarian carcinomaS Canevari, D Mezzanzanica, A Mazzoni, et al.
Gynecologic Oncology|October 1, 1996
Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancerG Bolis, I van Zainten-Przybysz, G Scarfone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimenG Bolis, G Scarfone, L Luchini, et al.
Regulatory Peptides|April 29, 1998
Chromatographic and immunological identification of GnRH (gonadotropin-releasing hormone) variants. Occurrence of mammalian and a salmon-like GnRH in the forebrain of an eutherian mammal: Hydrochaeris hydrochaeris (Mammalia, Rodentia)A D Montaner, G M Somoza, J A King, et al.
The Journal of Clinical Endocrinology and Metabolism|November 29, 2013
Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathwaysF Uberti, D Lattuada, V Morsanuto, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
International Journal of Cancer|October 23, 1997
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cellsV Ramakrishna, D R Negri, V Brusic, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancerF Crippa, G Bolis, E Seregni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxelM A Bookman, H Malmström, G Bolis, et al.
Gynecologic Oncology|January 16, 1999
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancerG Bolis, F Parazzini, G Scarfone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2006
Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II studyG Bolis, S Danese, S Tateo, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 1998
Approaches to implement bispecific antibody treatment of ovarian carcinomaS Canevari, D Mezzanzanica, A Mazzoni, et al.
Gynecologic Oncology|October 1, 1996
Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancerG Bolis, I van Zainten-Przybysz, G Scarfone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimenG Bolis, G Scarfone, L Luchini, et al.
Regulatory Peptides|April 29, 1998
Chromatographic and immunological identification of GnRH (gonadotropin-releasing hormone) variants. Occurrence of mammalian and a salmon-like GnRH in the forebrain of an eutherian mammal: Hydrochaeris hydrochaeris (Mammalia, Rodentia)A D Montaner, G M Somoza, J A King, et al.
The Journal of Clinical Endocrinology and Metabolism|November 29, 2013
Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathwaysF Uberti, D Lattuada, V Morsanuto, et al.
Pageof 13